Vericel Co. (NASDAQ:VCEL) Director Steven C. Gilman Sells 5,833 Shares

Vericel Co. (NASDAQ:VCEL) Director Steven C. Gilman sold 5,833 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $41.36, for a total transaction of $241,252.88. Following the sale, the director now owns 11,000 shares in the company, valued at approximately $454,960. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Vericel Trading Up 2.4 %

Shares of VCEL stock traded up $0.99 on Friday, reaching $41.66. The company’s stock had a trading volume of 250,030 shares, compared to its average volume of 430,068. The stock’s fifty day simple moving average is $45.34 and its 200-day simple moving average is $46.81. Vericel Co. has a 1 year low of $32.28 and a 1 year high of $54.10. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of -4,166.00 and a beta of 1.67.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). Vericel had a net margin of 0.37% and a return on equity of 0.35%. The firm had revenue of $52.70 million during the quarter, compared to analyst estimates of $52.59 million. During the same period last year, the firm posted ($0.11) earnings per share. Vericel’s revenue for the quarter was up 14.8% compared to the same quarter last year. Equities research analysts forecast that Vericel Co. will post 0.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on VCEL shares. StockNews.com cut shares of Vericel from a “hold” rating to a “sell” rating in a research report on Tuesday, October 8th. Canaccord Genuity Group started coverage on shares of Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 price objective on the stock. TD Cowen lifted their price objective on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. Truist Financial lifted their price objective on shares of Vericel from $56.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Finally, HC Wainwright lifted their price objective on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VCEL. Congress Asset Management Co. MA boosted its stake in Vericel by 509.1% during the first quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock worth $43,514,000 after buying an additional 699,147 shares during the period. TimesSquare Capital Management LLC purchased a new stake in shares of Vericel during the first quarter valued at about $12,782,000. Federated Hermes Inc. lifted its position in shares of Vericel by 34.9% during the second quarter. Federated Hermes Inc. now owns 840,787 shares of the biotechnology company’s stock valued at $38,575,000 after buying an additional 217,437 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Vericel by 51.5% during the second quarter. Victory Capital Management Inc. now owns 611,146 shares of the biotechnology company’s stock valued at $28,039,000 after buying an additional 207,714 shares during the last quarter. Finally, Geneva Capital Management LLC lifted its position in shares of Vericel by 43.6% during the first quarter. Geneva Capital Management LLC now owns 679,165 shares of the biotechnology company’s stock valued at $35,330,000 after buying an additional 206,202 shares during the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.